EP3522882A4 - Amino acid compositions and uses thereof - Google Patents

Amino acid compositions and uses thereof Download PDF

Info

Publication number
EP3522882A4
EP3522882A4 EP17859127.7A EP17859127A EP3522882A4 EP 3522882 A4 EP3522882 A4 EP 3522882A4 EP 17859127 A EP17859127 A EP 17859127A EP 3522882 A4 EP3522882 A4 EP 3522882A4
Authority
EP
European Patent Office
Prior art keywords
amino acid
acid compositions
compositions
amino
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17859127.7A
Other languages
German (de)
French (fr)
Other versions
EP3522882A1 (en
Inventor
Sadasivan Vidyasagar
Reshu GUPTA
Lianjie YIN
Astrid GROSCHE
Paul Gerson OKUNIEFF
Stephen GATTO
Daniel DENNISON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Entrinsic LLC
Original Assignee
University of Florida Research Foundation Inc
Entrinsic Health Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida Research Foundation Inc, Entrinsic Health Solutions Inc filed Critical University of Florida Research Foundation Inc
Publication of EP3522882A1 publication Critical patent/EP3522882A1/en
Publication of EP3522882A4 publication Critical patent/EP3522882A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP17859127.7A 2016-10-04 2017-10-04 Amino acid compositions and uses thereof Pending EP3522882A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662403965P 2016-10-04 2016-10-04
US201662421443P 2016-11-14 2016-11-14
PCT/US2017/055167 WO2018067717A1 (en) 2016-10-04 2017-10-04 Amino acid compositions and uses thereof

Publications (2)

Publication Number Publication Date
EP3522882A1 EP3522882A1 (en) 2019-08-14
EP3522882A4 true EP3522882A4 (en) 2020-06-24

Family

ID=61831937

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17859127.7A Pending EP3522882A4 (en) 2016-10-04 2017-10-04 Amino acid compositions and uses thereof

Country Status (9)

Country Link
US (1) US11576884B2 (en)
EP (1) EP3522882A4 (en)
JP (2) JP7267546B2 (en)
CN (2) CN115645388A (en)
AU (1) AU2017338887B2 (en)
BR (1) BR112019006742A2 (en)
CA (2) CA3039514C (en)
MX (1) MX2019003821A (en)
WO (1) WO2018067717A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993522B2 (en) 2010-09-24 2015-03-31 University Of Florida Research Foundation, Inc. Materials and methods for improving gastrointestinal function
MX361647B (en) 2013-03-11 2018-12-13 Univ Florida Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications.
BR112020020318A2 (en) * 2018-04-04 2021-01-05 University Of Florida Research Foundation, Incorporated COMPOSITIONS FOR SKIN TREATMENT
US20210212973A1 (en) * 2018-07-30 2021-07-15 Almeda Labs Llc Cardioprotective amino acid formulation
RU2709502C1 (en) * 2019-09-23 2019-12-18 Виктор Александрович Сисев Pharmaceutical composition for parenteral drip introduction
AU2021207295A1 (en) * 2020-01-13 2022-08-04 Monash University Compositions and methods
JP7470376B2 (en) 2020-03-31 2024-04-18 国立大学法人山口大学 Submandibular gland atrophy inhibitor and wound healing promoter
EP4175662A1 (en) * 2020-07-02 2023-05-10 University Of Florida Research Foundation, Incorporated Formulations for promoting hydration and methods of use thereof
CN114097952A (en) * 2020-08-28 2022-03-01 河北科星药业有限公司 Special nutritional additive for chinchilla, preparation method and application thereof
WO2023130094A2 (en) * 2022-01-03 2023-07-06 Entrinsic, LLC Formulations and methods for skin care
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011105640A (en) * 2009-11-17 2011-06-02 Otsuka Pharmaceut Co Ltd Airway resistance improving agent
US20130018080A1 (en) * 2009-11-27 2013-01-17 Isabella Arborio Mella Compositions comprising amino acids for treating chronic obstructive pulmonary disease
US20130071439A1 (en) * 2010-01-08 2013-03-21 President And Fellows Of Harvard College Methods and compositions for treating biofilms
WO2014164736A1 (en) * 2013-03-11 2014-10-09 University Of Florida Research Foundation, Incorporated Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications
WO2016085735A1 (en) * 2014-11-24 2016-06-02 Entrinsic Health Solutions, Llc Amino acid compositions for the treatment of symptoms of disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69430303T2 (en) 1991-03-05 2002-11-28 Aradigm Corp METHOD AND DEVICE FOR CORRECTING A ZERO SIGNAL OF A PRESSURE SENSOR FOR A FLOW METER
ES2284226T3 (en) 1991-07-02 2007-11-01 Nektar Therapeutics DEVICE FOR PROVIDING MEDICATIONS IN AEROSOL.
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
EP0810829B1 (en) 1995-02-23 2000-04-12 Novartis Nutrition AG Amino acid compositions and use thereof in clinical nutrition
WO1998029098A1 (en) 1996-12-31 1998-07-09 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
MXPA01002875A (en) 1998-11-13 2002-04-08 Los Angeles Childrens Hospital Methods of facilitating vascular growth.
GB0009056D0 (en) 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
CA2557814A1 (en) 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
US20070010459A1 (en) 2005-01-14 2007-01-11 Ying Liu Application of asiatic acid and its derivatives to treat pulmonary fibrosis
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
DK2164349T3 (en) * 2006-08-04 2014-12-15 Shs Int Ltd protein-FORMULA
US20110183040A1 (en) * 2007-08-03 2011-07-28 Ermolin Gennady A Amino Acid and Peptide Products
IT1396935B1 (en) 2009-11-26 2012-12-20 Solartium Entpr Ltd USE OF A COMBINATION FOR THE TREATMENT OF MUCOSITES INDUCED BY RADIATION OR CHEMOTHERAPY
US8993522B2 (en) 2010-09-24 2015-03-31 University Of Florida Research Foundation, Inc. Materials and methods for improving gastrointestinal function
JP2012214451A (en) * 2011-03-25 2012-11-08 En Otsuka Pharmaceutical Co Ltd Amino acid composition for inflammatory disease
EP2793813A1 (en) 2011-12-21 2014-10-29 Motolese, Pasquale Cosmetic composition and uses thereof in the treatment of lipodystrophies
US20140377374A1 (en) 2012-02-08 2014-12-25 University Of Florida Research Foundation, Inc. Materials and methods for treating diarrhea
DE102013224993A1 (en) 2013-12-05 2015-06-11 Henkel Ag & Co. Kgaa Hair treatment agent with substituted silicone (s)
US10413528B2 (en) 2014-10-20 2019-09-17 John H. Plumb Methods to inhibit infection during wound healing with topical compositions including amino acids

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011105640A (en) * 2009-11-17 2011-06-02 Otsuka Pharmaceut Co Ltd Airway resistance improving agent
US20130018080A1 (en) * 2009-11-27 2013-01-17 Isabella Arborio Mella Compositions comprising amino acids for treating chronic obstructive pulmonary disease
US20130071439A1 (en) * 2010-01-08 2013-03-21 President And Fellows Of Harvard College Methods and compositions for treating biofilms
WO2014164736A1 (en) * 2013-03-11 2014-10-09 University Of Florida Research Foundation, Incorporated Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications
WO2016085735A1 (en) * 2014-11-24 2016-06-02 Entrinsic Health Solutions, Llc Amino acid compositions for the treatment of symptoms of disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2018067717A1 *

Also Published As

Publication number Publication date
CA3135553C (en) 2024-05-21
CA3135553A1 (en) 2018-04-12
MX2019003821A (en) 2019-12-18
CN115645388A (en) 2023-01-31
WO2018067717A1 (en) 2018-04-12
JP2023100617A (en) 2023-07-19
US20210283081A1 (en) 2021-09-16
US11576884B2 (en) 2023-02-14
AU2017338887B2 (en) 2020-09-03
CA3039514A1 (en) 2018-04-12
EP3522882A1 (en) 2019-08-14
AU2017338887A1 (en) 2019-05-02
CN110062621A (en) 2019-07-26
CA3039514C (en) 2022-01-25
CN110062621B (en) 2022-11-01
JP7267546B2 (en) 2023-05-02
JP2019530750A (en) 2019-10-24
BR112019006742A2 (en) 2019-09-03

Similar Documents

Publication Publication Date Title
EP3522882A4 (en) Amino acid compositions and uses thereof
EP3347472A4 (en) Compositions comprising cyp76ad1- clade polypeptides and uses thereof
EP3413816A4 (en) Moisturizing compositions and uses thereof
EP3596104A4 (en) Compositions comprising pedf-derived short peptides and uses thereof
EP3503879A4 (en) Compositions and methods thereof
EP3370528A4 (en) Probiotic compositions and uses thereof
EP3436040A4 (en) Compositions containing tannic acids and uses thereof
EP3436083A4 (en) Novel compositions and methods
EP3494119A4 (en) Compounds and compositions and uses thereof
EP3432859A4 (en) Cosmetic compositions and uses thereof
EP3305802A4 (en) Novel peptide and composition containing the same
EP3134425A4 (en) Compositions comprising gluten peptides and uses thereof
EP3642219A4 (en) Peptide compositions and related methods
EP3149099A4 (en) Synthetic acid compositions and uses thereof
EP3310373A4 (en) Thiol-ene based peptide stapling and uses thereof
EP3288379A4 (en) Peptide compositions and methods of use
EP3237374A4 (en) Amino acid and peptide conjugates and uses thereof
EP3375772A4 (en) Novel heterocycle-containing amino acid compound and use thereof
EP3316871A4 (en) Talc-bound compositions and uses thereof
EP3490607A4 (en) Compounds and compositions and uses thereof
EP3423096A4 (en) Polymalic acid based nanoimmunoconjugates and uses thereof
HK1255012A1 (en) Amino acid-containing composition
EP3319930A4 (en) Methods and compositions for the stabilizaton of proteins
EP3302513A4 (en) Composition and uses thereof
EP3471710A4 (en) Anti-parasitic compositions and methods

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190502

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ENTRINSIC HEALTH SOLUTIONS, INC.

Owner name: THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCO

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200525

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/198 20060101ALI20200516BHEP

Ipc: A61K 31/195 20060101AFI20200516BHEP

Ipc: A61P 11/00 20060101ALI20200516BHEP

Ipc: A61K 31/197 20060101ALI20200516BHEP

Ipc: A61P 11/06 20060101ALI20200516BHEP

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED

Owner name: ENTRINSIC, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240402